Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 10/20 | 0.42 |
| ▸ | CACNA2D1 | P54289 | 10/20 | 0.42 |
| ▸ | WEE1 | P30291 | 1/20 | 0.40 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | ALB | P02768 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16824892 | 0.87 | WEE1 (0.51) | SLC6A2CACNA2D1WEE1MAPK14 | |
| SCHEMBL16824923 | 0.84 | WEE1 (0.50) | SLC6A2CACNA2D1WEE1MAPK14 | |
| SCHEMBL16824934 | 0.83 | WEE1 (0.45) | SLC6A2CACNA2D1WEE1MAPK14 | |
| SCHEMBL30656418 | 0.83 | WEE1 (0.45) | SLC6A2CACNA2D1WEE1MAPK14 | |
| SCHEMBL1813022 | 0.80 | MAPT (0.42) | MAPTKDM4EALDH1A1WEE1GPBAR1 | |
| SCHEMBL18186297 | 0.79 | SLC6A2 (0.42) | SLC6A2CACNA2D1WEE1MAPK14 | |
| SCHEMBL20874020 | 0.77 | WEE1 (0.53) | WEE1 | |
| SCHEMBL18186255 | 0.76 | SLC6A2 (0.43) | MAPTKDM4EALDH1A1SLC6A2CACNA2D1 | |
| SCHEMBL20180609 | 0.75 | WEE1 (0.41) | MAPTKDM4EALDH1A1SLC6A2CACNA2D1 | |
| SCHEMBL29506611 | 0.75 | WEE1 (0.41) | MAPTKDM4EALDH1A1SLC6A2CACNA2D1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9850247-B2 | Pyrimidopyrimidinones useful as Wee-1 kinase inhibitors | ALMAC HOUSE (GB) | 2017-12-26 | — | — | US | disclosed |
| EP-3083625-B1 | PYRIMIDOPYRIMIDINONES USEFUL AS WEE-1 KINASE INHIBITORS | ALMAC DISCOVERY LTD (GB) | 2017-11-01 | — | — | EP | disclosed |
| US-20160318936-A1 | PYRIMIDOPYRIMIDINONES USEFUL AS WEE-1 KINASE INHIBITORS | ALMAC DISCOVERY LIMITED (GB) | 2016-11-03 | — | — | US | disclosed |
| EP-3083625-A1 | PYRIMIDOPYRIMIDINONES USEFUL AS WEE-1 KINASE INHIBITORS | Almac Discovery Limited (GB) | 2016-10-26 | — | — | EP | disclosed |
| WO-2015092431-A1 | PYRIMIDOPYRIMIDINONES USEFUL AS WEE-1 KINASE INHIBITORS | ALMAC DISCOVERY LIMITED (GB) | 2015-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160318936-A1 | PYRIMIDOPYRIMIDINONES USEFUL AS WEE-1 KINASE INHIBITORS | WEE1, WEE2, NME1 | MAPT 3728/4885KDM4E 652/4885ALDH1A1 1940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.